CU20250010A7 - Composición farmacéutica de virus adenoasociado recombinante - Google Patents

Composición farmacéutica de virus adenoasociado recombinante

Info

Publication number
CU20250010A7
CU20250010A7 CU2025000010A CU20250010A CU20250010A7 CU 20250010 A7 CU20250010 A7 CU 20250010A7 CU 2025000010 A CU2025000010 A CU 2025000010A CU 20250010 A CU20250010 A CU 20250010A CU 20250010 A7 CU20250010 A7 CU 20250010A7
Authority
CU
Cuba
Prior art keywords
pharmaceutical composition
recombinant
adenoassociated virus
recombinant adenoassociated
virus
Prior art date
Application number
CU2025000010A
Other languages
English (en)
Inventor
Lina Igorevna Fedorenko
Ekaterina Aleksandrovna Lomkova
Dmitry Valentinovich Morozov
Galina Sergeevna Nagibina
Aleksandra Aleksandrovna Sozonova
Dmitrii Aleksandrovich Tolstykh
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2022130458A external-priority patent/RU2821530C2/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of CU20250010A7 publication Critical patent/CU20250010A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Manufacturing & Machinery (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

<p>La presente invención se refiere al campo de los productos farmacéuticos, la terapia génica y la medicina, y más específicamente a composiciones farmacéuticas estables que comprenden un vector basado en un virus recombinante sin envoltura, en particular un virus adenoasociado recombinante (rAAV). La invención se refiere a diversas formas de realización de la composición y asegura la creación de composiciones altamente estables que contienen un vector basado en un virus adenoasociado recombinante. </p>
CU2025000010A 2022-11-24 2023-11-23 Composición farmacéutica de virus adenoasociado recombinante CU20250010A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2022130458A RU2821530C2 (ru) 2022-11-24 Фармацевтическая композиция безоболочечного вируса
PCT/RU2023/050271 WO2024112230A1 (en) 2022-11-24 2023-11-23 Pharmaceutical composition of non-enveloped virus

Publications (1)

Publication Number Publication Date
CU20250010A7 true CU20250010A7 (es) 2026-01-12

Family

ID=91196430

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2025000010A CU20250010A7 (es) 2022-11-24 2023-11-23 Composición farmacéutica de virus adenoasociado recombinante

Country Status (20)

Country Link
EP (1) EP4622627A1 (es)
JP (1) JP2025539388A (es)
KR (1) KR20250105674A (es)
CN (1) CN118414175A (es)
AR (1) AR131087A1 (es)
AU (1) AU2023385019A1 (es)
CL (1) CL2025001538A1 (es)
CO (1) CO2025006850A2 (es)
CU (1) CU20250010A7 (es)
DO (1) DOP2025000121A (es)
GE (1) GEAP202516788A (es)
IL (1) IL321096A (es)
JO (1) JOP20250125A1 (es)
MX (1) MX2025006088A (es)
PE (1) PE20251889A1 (es)
PY (1) PY2395245A (es)
TW (1) TW202426017A (es)
UY (1) UY40524A (es)
WO (1) WO2024112230A1 (es)
ZA (1) ZA202504716B (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
EP1751275B1 (en) * 2004-06-01 2017-08-16 Avigen, Inc. Compositions and methods to prevent aav vector aggregation
GB201513010D0 (en) * 2015-07-23 2015-09-09 Glaxosmithkline Biolog Sa Novel formulation
PT3534922T (pt) * 2016-11-04 2024-06-07 Takeda Pharmaceuticals Co Formulações de vírus adenoassociado

Also Published As

Publication number Publication date
CN118414175A (zh) 2024-07-30
CL2025001538A1 (es) 2025-08-18
TW202426017A (zh) 2024-07-01
WO2024112230A1 (en) 2024-05-30
PE20251889A1 (es) 2025-07-25
GEAP202516788A (en) 2025-08-11
EP4622627A1 (en) 2025-10-01
PY2395245A (es) 2024-07-18
ZA202504716B (en) 2026-02-25
KR20250105674A (ko) 2025-07-08
AR131087A1 (es) 2025-02-12
MX2025006088A (es) 2025-07-01
IL321096A (en) 2025-07-01
AU2023385019A1 (en) 2025-06-12
JP2025539388A (ja) 2025-12-05
CO2025006850A2 (es) 2025-10-09
DOP2025000121A (es) 2025-06-30
UY40524A (es) 2024-04-30
JOP20250125A1 (ar) 2025-05-22

Similar Documents

Publication Publication Date Title
Lamichhane et al. Type I interferons are important co‐stimulatory signals during T cell receptor mediated human MAIT cell activation
BR112022022644A2 (pt) Composições de vírus adeno-associados compatíveis com espécies cruzadas e método de uso destas
Taylor et al. Antiviral effects of menthol on Coxsackievirus B
MX2024009660A (es) Variantes de capside de aav y usos de las mismas.
Niranjan et al. Melatonin attenuated mediators of neuroinflammation and alpha-7 nicotinic acetylcholine receptor mRNA expression in lipopolysaccharide (LPS) stimulated rat astrocytoma cells, C6
Nchioua et al. SARS-CoV-2 variants of concern hijack IFITM2 for efficient replication in human lung cells
CO2024000073A2 (es) Composición farmacéutica de virus no encapsulado
ES2163394T3 (es) Regiones serorreactivas situadas en las proteinas e1 y e2 de hpv16.
Guo et al. Inhibitory effect of iota-carrageenan on porcine reproductive and respiratory syndrome virus in vitro
MX2023008671A (es) Composicion farmaceutica.
CU20250010A7 (es) Composición farmacéutica de virus adenoasociado recombinante
Choudhary et al. Unraveling antiviral efficacy of multifunctional immunomodulatory triterpenoids against SARS‐COV‐2 targeting main protease and papain‐like protease
Wu et al. CSFV restricts necroptosis to sustain infection by inducing autophagy/mitophagy-targeted degradation of RIPK3
Yamamoto et al. Current status and perspectives of therapeutic antibodies targeting the spike protein S2 subunit against SARS-CoV-2
JOP20230296A1 (ar) تركيبات وطرائق لتحسين الوظيفة البصرية
He et al. Baicalin inhibits infectious bronchitis virus replication via MAVS-dependent interferon-β upregulation and mitochondrial function preservation
Gholami et al. Computational peptide engineering approach for selection of the new C05 antibody-driven peptide with potency to blocking influenza a virus attachment; from in silico to in vivo
Ekchariyawat et al. Involvement of GRIM-19 in apoptosis induced in H5N1 virus-infected human macrophages
CL2025001546A1 (es) Composición de insulina de acción rápida (variantes)
PE20252741A1 (es) Formulaciones de dosis de una sola unidad de alta concentracion y metodos de uso de estas
Akisawa et al. Fragment Molecular Orbital Based Interaction Analyses on Complexes Between RBD Variants and ACE2
Melcer Contribution of the CO2 laser in the sterilization of various infections of dental origin
AR124660A1 (es) Composición farmacéutica
AR132584A1 (es) Composiciones y métodos para el tratamiento de trastornos relacionados con la deficiencia de proteína de unión a sintaxina 1
CO2025009325A2 (es) Formulaciones de virus adenoasociados